SCHEMBL25922340

SCHEMBL25922340

CCN1C(=O)CSc2ccc(C(=O)Nc3ccc(S(=O)(=O)N4CCCCC4)cc3)cc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTDSP1 Q9GZU7 1/20 0.64
▸ POLB P06746 2/20 0.61
▸ USP2 O75604 4/20 0.58
▸ ALDH1A1 P00352 4/20 0.58
▸ TSHR P16473 2/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ MAPT P10636 4/20 0.56
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ GAA P10253 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ LMNA P02545 1/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ MAPK1 P28482 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ RXFP1 Q9HBX9 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25922300 0.91 CTDSP1 (0.61) CTDSP1POLBUSP2ALDH1A1TSHR
SCHEMBL25921866 0.88 CYP1A2 (0.58) CTDSP1POLBUSP2ALDH1A1TSHR
SCHEMBL30270587 0.88 CYP1A2 (0.58) CTDSP1POLBUSP2ALDH1A1TSHR
SCHEMBL25922279 0.88 CTDSP1 (0.58) CTDSP1POLBALDH1A1NPSR1MAPT
SCHEMBL25927899 0.86 CTDSP1 (0.55) CTDSP1POLBUSP2ALDH1A1TSHR
SCHEMBL25922344 0.86 CYP1A2 (0.56) CTDSP1POLBUSP2ALDH1A1TSHR
SCHEMBL25922275 0.83 TP53 (0.59) CTDSP1POLBUSP2ALDH1A1TSHR
SCHEMBL24125006 0.83 ALDH1A1 (0.59) CTDSP1POLBUSP2ALDH1A1TSHR
SCHEMBL25930932 0.79 MAPT (0.52) CTDSP1POLBUSP2ALDH1A1TSHR
SCHEMBL25927886 0.77 MAPT (0.58) POLBUSP2ALDH1A1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 CTDSP1 2570/4885POLB 2630/4885USP2 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback